Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Kids with type 2 diabetes now have a new option: the FDA has approved Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available for children aged 10 and older. The approval, backed by adult ONWARDS trial data and a pediatric pharmacokinetic study, could ease the burden of daily injections and help improve adherence in young patients.
Managing type 2 diabetes in children just got a little easier. The FDA has approved Awiqli (insulin icodec-abae, Novo Nordisk) for children aged 10 and older with type 2 diabetes — making it the first once-weekly basal insulin approved for a pediatric population. Previously approved for adults in March 2026, the expanded indication was supported by data from the adult ONWARDS clinical trials plus a single-dose pharmacokinetic study in children aged 10–17.
The move is significant because type 2 diabetes in children tends to follow a more aggressive course than in adults, and sticking to a daily injection routine can be a real challenge for kids and families. A once-weekly option could meaningfully reduce that burden and open the door to more personalized care.
Key Takeaways:
Why it matters: For over two decades, daily basal insulin injections have been the standard in pediatric diabetes care. A once-weekly alternative could reduce administration barriers, improve adherence, and give clinicians and families more flexibility in tailoring treatment to individual lifestyles.
